Vericel Corp (VCEL) FY2025 10-K Annual Report
Vericel Corp (VCEL) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 26, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Vericel Corp FY2025 10-K Analysis
Business Overview
- • Core business: advanced autologous cell therapies and specialty biologics for sports medicine and severe burn care markets
- • New product launch: MACI Arthro arthroscopic delivery system approved August 2024 and commercially available Q3 2024 with custom instruments
- • Strategic shift: expanded target surgeon base from 5,000 to 7,000 to include high-volume arthroscopic knee cartilage repair surgeons
- • Notable metric: MACI commercial team expanded by ~30% in late 2025 to support growth initiatives
- • Unique fact: Initiated MASCOT clinical trial in Q4 2025, first randomized study of MACI for ankle cartilage defects (osteochondral lesion of the talus)
Management Discussion & Analysis
- • Revenue not explicitly stated, but sales volume increase indicated by accounts receivable growth and higher net income $16.5M in 2025 vs $10.4M in 2024
- • Net income $16.5M (2025), operating expenses include $38.8M stock compensation, no explicit margin % reported
- • No segment breakdown provided for best/worst performing segments
- • Operating cash flow $51.9M (2025) vs $58.2M (2024); investing cash outflows $44M net in 2025 vs $79M in 2024; financing cash inflows $7.1M (2025) vs $19M (2024) from stock option exercises less tax withholdings
- • Management expects current liquidity (cash + investments + borrowing capacity) sufficient for 12+ months; risks include R&D pace, clinical trials, patent costs, manufacturing capacity, acquisitions, and macroeconomic factors
Risk Factors
- • Regulatory risk: potential penalties from FDA or state agencies for off-label promotion or anti-kickback/anti-bribery law violations
- • Geopolitical risk: supply disruption of NexoBrid due to Middle East conflicts or China-Taiwan tensions, impacting commercial success
- • Operational risk: dependency on third-party manufacturer Matricel GmbH for critical components of MACI/Epicel cell manufacturing
- • Market disruption risk: competitive pressure from emerging artificial intelligence technologies affecting product innovation and adoption
- • Financial risk: key-person dependency on senior manufacturing, quality, and management personnel critical to ongoing operations
Vericel Corp FY2025 Key Financial MetricsXBRL
Revenue
$276M
▲ +16.5% YoY
Net Income
$17M
▲ +59.4% YoY
Gross Margin
74.4%
▲ +187bp YoY
Operating Margin
4.0%
▲ +209bp YoY
Net Margin
6.0%
▲ +161bp YoY
ROE
4.7%
▲ +111bp YoY
Total Assets
$488M
▲ +12.8% YoY
EPS (Diluted)
$0.32
▲ +60.0% YoY
Operating Cash Flow
$52M
▼ -10.8% YoY
Source: XBRL data from Vericel Corp FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Vericel Corp
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.